Vivoryon Therapeutics NV
AEX:VVY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivoryon Therapeutics NV
Additional Paid In Capital
Vivoryon Therapeutics NV
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Vivoryon Therapeutics NV
AEX:VVY
|
Additional Paid In Capital
€177.3m
|
CAGR 3-Years
26%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Additional Paid In Capital
€1.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Additional Paid In Capital
$599.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Biotest AG
XETRA:BIO
|
Additional Paid In Capital
€219.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Vivoryon Therapeutics NV
Glance View
The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.
See Also
What is Vivoryon Therapeutics NV's Additional Paid In Capital?
Additional Paid In Capital
177.3m
EUR
Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's Additional Paid In Capital amounts to 177.3m EUR.
What is Vivoryon Therapeutics NV's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
23%
Over the last year, the Additional Paid In Capital growth was 19%. The average annual Additional Paid In Capital growth rates for Vivoryon Therapeutics NV have been 26% over the past three years , 15% over the past five years , and 23% over the past ten years .